. 2016 Apr 7;6:24097. doi: 10.1038/srep24097

Table 2. Meta-analysis of the association between TP53 Arg72Pro polymorphism and leukemia.

Subgroup	NO.	C vs. G			CC vs. GG			CC + GC vs. GG			CC vs. GC + GG
Subgroup	NO.	OR(95% CI)	P_h	P_OR	OR (95% CI)	P_h	P_OR	OR(95% CI)	P_h	P_OR	OR(95% CI)	P_h	P_OR
Overall	14	1.09(0.93–1.26)	0.000	0.272	1.24(0.91–1.69)	0.001	0.203	1.04(0.85–1.28)	0.001	0.530	1.23(0.96–1.57)	0.014	0.106
Ethnicity
Asian	8	1.02(0.86–1.20)	0.012	0.847	1.07(0.77–1.49)	0.024	0.678	0.98(0.76–1.27)	0.011	0.894	1.16(0.96–1.38)	0.130^*	0.120^*
Caucasian	5	1.15(0.83–1.59)	0.002	0.415	1.44(0.68–3.04)	0.005	0.337	1.11(0.78–1.59)	0.018	0.552	1.44(0.76–2.72)	0.022	0.263
Mixed	1	2.11(1.15–3.86)	–	0.016	5.40(1.03–28.19)	–	0.046	2.20(1.03–4.70)	–	0.041	4.17(0.83–21.04)	–	0.084
Source of control
Population-based	13	0.88(0.74–1.04)	0.000	0.127	0.78(0.55–1.10)	0.001	0.158	0.74(0.56–0.98)	0.005	0.038	0.93(0.75–1.16)	0.004	0.529
Hospital-based	2	0.90(0.71–1.16)	0.197^*	0.423	0.83(0.51–1.37)	0.185^*	0.469	0.97(0.63–1.49)	0.353^*	0.885	0.81(0.55–1.18)	0.214^*	0.267
Clinical types
AML	7	0.98(0.88–1.10)	0.179^*	0.730^*	1.00(0.79–1.27)	0.208^*	0.986^*	0.91(0.72–1.16)	0.048	0.448	1.11(0.89–1.37)	0.277^*	0.351^*
ALL	5	1.33(0.97–1.82)	0.002	0.078	1.83(0.95–3.50)	0.003	0.069	1.26(0.84–1.90)	0.008	0.266	1.73(1.07–2.81)	0.022	0.025
Others^#	4	0.97(0.68–1.39)	0.035	0.882	0.95(0.61–1.48)	0.087^*	0.827^*	0.97(0.73–1.28)	0.056^*	0.823^*	0.93(0.62–1.40)	0.129	0.722^*

OR odds ratio; 95% CI, 95% confidence interval; P_OR, pool P value; P_h, P value of heterogeneity test; NA, data not available.

^*Estimates for fixed-effects model; otherwise, random-effects model was used.

^#Others include chronic lymphocytic leukemia, chronic myeloid leukemia, adult T-cell leukemia, and mixed types.